Clofibrate
Top View
- Lipotropics, Other
- Research Article Treatment with PPAR Agonist Clofibrate Inhibits the Transcription and Activation of Srebps and Reduces Tr
- Ciprofibrate 100Mg Tablets
- Peroxisome Proliferator-Activated Receptors (Ppars): Novel Therapeutic Targets in Renal Disease
- (PPAR) Agonists in Substance Use Disorders: a Synthesis of Preclinical and Human Evidence
- Pparα Ligand Clofibrate Ameliorates Blood Pressure and Vascular Reactivity in Spontaneously Hypertensive Rats
- Changes Highlighted Final Version Date of Issue
- Lipid Management in Patients with Endocrine Disorders: an Endocrine
- Peroxisome Proliferator–Activated Receptor- Regulates Fatty Acid Utilization in Primary Human Skeletal Muscle Cells
- Lipofen® (Fenofibrate Capsules USP) for Oral Use 50 Mg and 150 Mg
- Etofibrate but Not Controlled-Release Niacin Decreases LDL Cholesterol and Lipoprotein (A) in Type Iib Dyslipidemic Subjects
- Cholesterol Lowering Medications
- Accessibility Improving Information Using Online Patient Drug Reviews
- Combined Use of a Fibrate and Orlistat for the Treatment of Obesity
- Comparative Study on the in Vivo and in Vitro Antilipolytic Effects of Etofibrate, Nicotinic Acid and Clofibrate in the Rat
- Combined Effects of Probucol and Bezafibrate on Lipoprotein Metabolism and Liver Cholesteryl Ester Transfer Protein Mrna in Chol
- Bempedoic Acid and Inclisiran for Patients with Heterozygous Familial Hypercholesterolemia and for Secondary Prevention of ASCVD: Effectiveness and Value
- Lipotropics, Other Therapeutic Class Review (TCR)